cancer. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. Current efforts are focused in emerging markets where health challenges are prevalent, treatment expenses often limit availability for patients, and regulatory approval has already been granted. The company will also continue to pursue regulatory approval and commercialization initiatives in the U.S. and other international markets.

Biostax intends to advance select and efficient small-scale biotechnology, pharmaceutical and MedTech programs through subsidiaries, investment vehicles and partnerships utilizing a biotech portfolio hub-and-spoke business model.